By Susanna Moon
Chicago, Jan. 29 - JPMorgan Chase & Co. priced $1.29 million of autocallable contingent interest notes due Feb. 12, 2014 linked to Valeant Pharmaceuticals International, Inc. shares, according to a 424B2 filing with the Securities and Exchange Commission.
If Valeant shares close at or above the 75% barrier level on any quarterly review date other than the final review date, the notes will pay a coupon at an annualized rate of 18.35% for that quarter.
If Valeant shares close at or above the initial share price on any of the first three quarterly review dates, the notes will be called at par plus the coupon.
If the notes have not been called, the payout at maturity will be par plus the coupon unless the stock finishes below the barrier level, in which case investors will be fully exposed to any losses.
J.P. Morgan Securities LLC is the underwriter.
| Issuer: | JPMorgan Chase & Co.
|
| Issue: | Autocallable contingent interest notes
|
| Underlying stock: | Valeant Pharmaceuticals International, Inc. (Symbol: VRX)
|
| Amount: | $1.29 million
|
| Maturity: | Feb. 12, 2014
|
| Coupon: | 18.35% annualized if the closing price of Valeant shares is at or above barrier price for that quarter
|
| Price: | Par
|
| Payout at maturity: | Par in cash unless Valeant shares finish below barrier price, in which case investors share in losses
|
| Call: | At par plus contingent coupon if stocks closes above initial price on any review date other than the final review date
|
| Initial share price: | $65.64
|
| Barrier price: | $49.23, 75% of initial share price
|
| Pricing date: | Jan. 25
|
| Settlement date: | Jan. 30
|
| Underwriter: | J.P. Morgan Securities LLC
|
| Fees: | 1%
|
| Cusip: | 48126DUR8
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
